TG Therapeutics, Inc.
TGTXNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $8.52B
- P/E (TTM)
- 19.30
- Forward P/E
- 9.60
- Dividend yield
- -
- 52-week range
- $26.76$59.30
- Volume (live)
- -
- Avg. volume (3M)
- 1.74M
TG Therapeutics (TGTX) Stock Price & Financial Analysis
TG Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $51.83 - $55.81 |
|---|---|
| 52-Week High | $59.30 |
| 52-Week Low | $26.76 |
| Open | $52.56 |
| Volume (last close) | 1.98M |
| Average Volume (3M) | 1.74M |
| Revenue (TTM) | 799.54M |
|---|---|
| Net Income (TTM) | 441.49M |
| Free Cash Flow (TTM) | -560.00K |
| EPS (TTM) | $2.77 |
| Profit Margin | 55.22% |
| Operating Margin | 17.05% |
| Return on Equity (ROE) | 73.08% |
| Debt to Equity | 1.25 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 8.52B |
|---|---|
| Shares Outstanding | 157.28M |
| P/E Ratio (TTM) | 19.30 |
| Forward P/E | 9.60 |
| Price to Sales (P/S) | 10.66 |
| Price to Book (P/B) | 14.10 |
| EV/EBITDA | 64.34 |
| 50-Day MA | $54.32 |
|---|---|
| 200-Day MA | $42.73 |
| 1-Year Change | +58.73% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
TG Therapeutics at a Glance
As of the Oct 23, 2026 close, TG Therapeutics (TGTX) has a market capitalization of $8.52B. The stock trades at 19.3× trailing earnings, 9.6× forward earnings and 10.7× sales. Over the trailing twelve months it earned $441.49M on revenue of $799.54M (a 55.2% profit margin) and burned $560.00K of free cash flow. Revenue grew 76.1% year over year.
As of its latest reported balance sheet, it holds $482.57M in cash and securities against $754.44M of debt, a net debt position of $271.87M.
TG Therapeutics does not currently pay a dividend.
The share price is up 58.7% over the past year. At $54.17 (the Oct 23, 2026 close) it sits within its 52-week range of $26.76 to $59.30, above its 200-day moving average of $42.73.
Based on 6 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $66.40, 22.6% above the Oct 23, 2026 close.
Frequently Asked Questions About TG Therapeutics
What is the current stock price for TGTX?
As of the Oct 23, 2026 close, TGTX stock trades at $54.17. The 52-week range is $26.76–$59.30, with a day range of $51.83–$55.81.
What is the P/E ratio for TGTX?
As of the Oct 23, 2026 close, TG Therapeutics's trailing twelve-month (TTM) P/E ratio is 19.3, meaning investors pay $19.3 for every $1 of annual earnings. The forward P/E is 9.6, reflecting analyst expectations for future earnings. TG Therapeutics operates in the Healthcare sector.
Does TGTX pay dividends?
TG Therapeutics does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for TGTX?
Based on ratings from 6 professional analysts over the last 90 days, the consensus for TGTX is Buy. The average 12-month price target is $66.40, a 22.6% upside from the Oct 23, 2026 close of $54.17.
What is the market cap of TGTX?
As of the Oct 23, 2026 close, TG Therapeutics's market capitalization is $8.52B, classifying it as a mid-cap company. TG Therapeutics operates in the Healthcare sector within the Biotechnology industry.